Award of Shares under Share Incentive Plan

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, implemented an HMRC approved Share Incentive Plan ("SIP") during 2020 which is available to all of the Company's UK based employees, including Directors.

Under the SIP, shares are acquired in four ways:

• Partnership Shares where an employee can spend up to a £1,800 or 10% of their pre-tax income, whichever is the lower;
• Matching Shares, where Creo can give up to two free Matching Shares for each Partnership Share bought. The plan requires employees to remain in employment for three years to benefit from the Matching Shares;
• Free Shares, where Creo can give up to £3,600 of free shares in any tax year; and
• Dividend Shares where additional shares can be bought with any dividends paid.

The Company has been notified that Fiduchi Trustees (UK) Limited ("Fiduchi"), the independent trustee of the SIP, acquired, in accordance with the SIP's rules and on behalf of SIP participants, 248,132 ordinary shares in the Company ("Ordinary Shares"), at a price of £0.191 per Ordinary Share on 16 January 2025 to meet its obligations under the SIP. Under the terms of the SIP, the Company is required to issue to the SIP, two Ordinary Shares in the Company for each Partnership Share purchased (being 496,264 Ordinary Shares in total). Fiduchi holds 171,924 unallocated shares within the SIP (being shares previously allocated to employees who ceased employment before the shares had vested) which can be utilised to part satisfy the Company's obligation. Accordingly, 324,340 new Ordinary Shares are required to be issued by the Company to be held by Fiduchi as trustee of the SIP.

Craig Gulliford, Richard Rees and Christopher Hancock, executive directors of the Company (the "Participating Directors") have received Partnership Shares at a price of £0.191 per share and Matching Shares at a price of £0.001 per share in accordance with terms of the SIP (the "Transaction"). Following this the Participating Directors' shareholdings in the Company are as set out in the table below:

Accordingly, the Company announces that it has made an application for 324,340 new Ordinary Shares to be admitted to trading on AIM. It is expected that admission will take place on 28 January 2025. Following the allotment and issue, the Company's issued share capital consists of 412,473,319 Ordinary Shares. The Company does not hold any shares in Treasury. As such the total number of shares in issue with voting rights is 412,473,319.

Total Voting Rights (TVR)

The above figure of 412,473,319 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Notes:

1 Includes shares held by Mr Gulliford's wife.

2 Includes shares held by Mr Rees's wife.

• Description of the financial instrument Ordinary Shares
• Nature of the transaction Purchase of Ordinary Shares under Share Incentive Plan
• Price(s) and volume(s) Prices Volume(s) £0.191 4,712
• Aggregated information Aggregated volume Price N/A - Single transaction
• Date of the transaction 2025-01-16 GMT
• Place of the transaction London Stock Exchange

1. Details of PDMR

• Name Craig Gulliford
• Position / status CEO
• Initial notification / amendment Initial notification
• Description of the financial instrument Ordinary Shares
• Nature of the transaction Award of Ordinary Shares under Share Incentive Plan
• Price(s) and volume(s) Prices Volume(s) £0.001 9,424
• Aggregated information Aggregated volume Price N/A - Single transaction
• Date of the transaction 2025-01-20 GMT
• Place of the transaction London Stock Exchange

1. Details of PDMR

• Name Richard Rees
• Position / status CFO
• Initial notification / amendment Initial notification
• Description of the financial instrument Ordinary Shares
• Nature of the transaction Purchase of Ordinary Shares under Share Incentive Plan
• Price(s) and volume(s) Prices Volume(s) £0.191 4,712
• Aggregated information Aggregated volume Price N/A - Single transaction
• Date of the transaction 2025-01-16 GMT
• Place of the transaction London Stock Exchange

1. Details of PDMR

• Name Richard Rees
• Position / status CFO
• Initial notification / amendment Initial notification
• Description of the financial instrument Ordinary Shares
• Nature of the transaction Award of Ordinary Shares under Share Incentive Plan
• Price(s) and volume(s) Prices Volume(s) £0.001 9,424
• Aggregated information Aggregated volume Price N/A - Single transaction
• Date of the transaction 2025-01-20 GMT
• Place of the transaction London Stock Exchange

1. Details of PDMR

• Name Christopher Hancock
• Position / status CTO
• Initial notification / amendment Initial notification
• Description of the financial instrument Ordinary Shares
• Nature of the transaction Purchase of Ordinary Shares under Share Incentive Plan
• Price(s) and volume(s) Prices Volume(s) £0.191 4,712
• Aggregated information Aggregated volume Price N/A - Single transaction
• Date of the transaction 2025-01-20 GMT
• Place of the transaction London Stock Exchange

1. Details of PDMR

• Name Christopher Hancock
• Position / status CTO
• Initial notification / amendment Initial notification
• Description of the financial instrument Ordinary Shares
• Nature of the transaction Award of Ordinary Shares under Share Incentive Plan
• Price(s) and volume(s) Prices Volume(s) £0.001 9,424
• Aggregated information Aggregated volume Price N/A - Single transaction
• Date of the transaction 2025-01-20 GMT
• Place of the transaction London Stock Exchange